Brief: Eisai: To Divest Rights For Merislon® And Myonal® In Japan To Kaken Pharmaceutical
29/03/2024 01:02
March 29 (Reuters) -
* EISAI: TO DIVEST RIGHTS FOR MERISLON® AND MYONAL® IN JAPAN
TO
KAKEN PHARMACEUTICAL
* EISAI: WILL RECEIVE 3.8 BILLION YEN FOR THE TRANSFER, NO
CHANGES
TO CONSOLIDATED FY2024 FINANCIAL FORECAST ANTICIPATED
Source text: https://www.eisai.com/news/2024/pdf/enews202422pdf.pdf
Further company coverage: 4521.T
(Reporting by Kantaro Komiya)
((Kantaro.Komiya@thomsonreuters.com;))